Loading
A phase 1/2 trial of AZD7789 in non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer is a phase 1/2 interventional study registered as NCT04931654 by AstraZeneca, with 136 participants enrolled, started 2021-09-28 and due to reach its primary completion in 2024-12-04. Interventions recorded: AZD7789.
Shares AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Non-small-cell lung cancer and the tag pipeline.